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Purpose: Emerging data suggests coronavirus disease 2019 (COVID-19) has extrapulmonary manifestations 
but its renal manifestations are not clearly defined. We aimed to evaluate renal complications of COVID-19 
and their incidence using a systematic meta-analysis. 
Design: Observational studies reporting renal complications in COVID-19 patients were sought from 
MEDLINE, Embase and the Cochrane Library from 2019 to June 2020. The nine-star Newcastle-Ottawa 
Scale was used to evaluate methodological quality. Incidence with 95% confidence intervals (CIs) were 
pooled using random-effects models. Results: We included 22 observational cohort studies comprising of 
17,391 COVID-19 patients. Quality scores of studies ranged from 4-6. The pooled prevalence of pre-existing 
chronic kidney disease (CKD) and end-stage kidney disease was 5.2% (2.8-8.1) and 2.3% (1.8-2.8) 
respectively. The pooled incidence over follow-up of 2-28 days was 12.5% (10.1-15.0) for electrolyte 
disturbance (eg, hyperkalaemia), 11.0% (7.4-15.1) for acute kidney injury (AKI) and 6.8% (1.0-17.0) for renal 
replacement therapy (RRT). In subgroup analyses, there was a higher incidence of AKI in US populations and 
groups with higher prevalence of pre-existing CKD. Conclusions: Frequent renal complications reported 
among hospitalised COVID-19 patients are electrolyte disturbance, AKI and RRT. Aggressive monitoring and 
management of these renal complications may help in the prediction of favourable outcomes.  
Systematic review registration: PROSPERO 2020: CRD42020186873 






• COVID-19 affects multiple organs apart from the respiratory system; however, its renal 
manifestations are not clearly defined.  
• In this systematic meta-analysis of 22 observational cohort studies, the prevalence of pre-
existing chronic kidney disease (CKD) in COVID-19 patients was 5.2%. 
• The most frequent renal complication was electrolyte disturbance (particularly 
hyperkalaemia) with an incidence of 12.5% followed by acute kidney injury (AKI) with an 
incidence of 11.0%; US populations and groups with higher prevalence of CKD had 














Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 
(SARS CoV-2) was declared a global public health emergency on 30 January 2020. The COVID-19 pandemic 
has caused substantial morbidity and mortality worldwide(1) and poses the most significant modern-day 
public health challenge since the Spanish flu of 1918. Coronavirus disease 2019 predominantly affects the 
respiratory system, typically manifesting as acute respiratory distress syndrome (ARDS) and severe 
pneumonia in a few, whereas majority of patients are asymptomatic or present with mild symptoms.(2)  The 
most common symptoms of COVID-19 are fever, cough, myalgia or fatigue.(3) Older patients, males and 
those with pre-existing comorbidities such as cardiovascular disease (CVD), hypertension, chronic kidney 
disease, chronic liver disease and diabetes are reported to be more likely to be infected with SARS CoV-2(4) 
and are at highest risk for severe illness or death.(5, 6) Emerging data suggests that COVID-19 also affects 
multiple organs, leading to organ failure and eventually death.(7) Common cardiovascular complications 
reported to be associated with COVID-19 include myocardial injury and heart failure,(8) which have been 
shown to correlate with the severity of or mortality from COVID-19.(9) Further emerging data also suggests 
COVID-19 contributes to adverse renal manifestations such as acute kidney injury (AKI), which is also 
associated with severe COVID-19 or mortality.(10) Given the sparse data, the renal manifestations of 
COVID-19 are not clearly defined. Despite the rapidly growing knowledge base on the clinical course of the 
disease, no effective therapeutic agents have been identified. Further data on the clinical course of the disease 
could help in the development of effective treatment strategies. Understanding the interplay between COVID-
19 and its renal manifestations could assist in the management of patients. In this context, we sought to 
address the following questions using a first systematic meta-analysis of published evidence: (i) what are the 
renal complications associated with COVID-19? (ii) what is the incidence of these complications?  and (iii) 








Materials and methods 
Data sources and search strategy  
The review was based on a predefined protocol which was registered in the PROSPERO International 
prospective register of systematic reviews (CRD42020186873) and it was conducted in accordance with 
PRISMA and MOOSE guidelines (11, 12) (Supplementary materials 1-2). MEDLINE, Embase, and The 
Cochrane library were searched from 2019 to 13 June 2020 for published studies reporting on renal 
complications in patients with COVID-19. We combined search terms and key words related to the population 
(e.g., “COVID-19”, “SARS-CoV-2”) and outcomes (e.g., “kidney”, “renal”, “acute kidney injury”, “renal 
transplant therapy”, “albuminuria”) in humans, which was limited to only reports published in the English 
language given the potential for duplicate reporting using the same study participants.(13) The detailed search 
strategy can be found in Supplementary material 3. Titles and abstracts were screened for potential eligible 
studies following retrieval of citations. Following initial screening, full texts of potentially eligible studies 
were acquired for detailed evaluation. Manual scanning of key articles and review papers was conducted to 
identify additional articles missed by the search strategy. 
 
Study selection and eligibility criteria  
The protocol was pre-specified to include observational studies (prospective and retrospective, nested case-
control and case-control designs), non-randomised clinical studies and randomised controlled trials (RCTs) 
which reported renal complications in patients with COVID-19. Our protocol was pre-specified to include all 
renal complications anticipated to be reported by studies such as AKI, proteinuria, haematuria, albuminuria, 
electrolyte disturbance, renal acidosis and alkalosis, need for renal replacement therapy (RRT) and kidney 
transplant among others. We also sought for studies reporting information on any pre-existing renal conditions 
(e.g., CKD, end-stage kidney disease); however, they were not included if they did not report on any renal 







Data extraction and quality assessment 
Using a pre-designed data extraction form, the following data were extracted from the eligible studies: author 
and year of publication; study characteristics (design, location and date of data collection); patient 
characteristics (average age, sex, percentage of males, total number of patients, pre-existing renal conditions 
and their counts and follow-up duration or hospital stay); and renal complications and their counts. Data were 
extracted and analysed as reported. However, hyperkalaemia was reported by one study and was classified as 
an electrolyte disturbance to enhance consistency and enable pooling. To minimise over- and under-reporting 
and maintain consistency, extraction of prevalence and incidence data employed an intention-to-treat 
principle. Methodological quality of studies was assessed using the nine-star Newcastle-Ottawa Scale 
(NOS),(14) a tool which has been validated for assessing the quality of non-randomised studies.  
 
Statistical analysis  
Pooled prevalence of pre-existing renal conditions (eg, CKD) with 95% confidence intervals (CIs) was 
calculated from the number of pre-existing renal conditions/total number of patients with COVID-19 in the 
study. Incidence of renal complications with 95% confidence intervals CIs was estimated from the number of 
patients experiencing the specific renal complication within period of follow-up (hospital stay)/total number 
of patients with COVID-19). Given that the data was binary with some low counts, the Freeman-Tukey 
variance stabilising double arcsine transformation (15) was used in calculating prevalence and incidence 
estimates as done in previous reports.(16-18) Heterogeneity was assessed and quantified using Cochrane χ2 
and I2 statistics.(19) We also estimated 95% prediction intervals to determine the degree of heterogeneity, as 
they provide a region in which about 95% of the true effects of a new study are expected to be found.(20, 21) 
Pre-defined study-level characteristics such as location, age and comorbidities which may explain 
heterogeneity were explored using stratified analysis and random effects meta-regression. STATA release MP 
16 (StataCorp LP, College Station, TX, USA) was used for all statistical analyses.  
 
Results 




The process of study selection is presented in Figure 1. Overall, a total of 109 articles were identified from 
the search of major databases and manual scanning of reference lists of relevant articles. After initial 
screening based on titles and abstracts, full texts of 28 articles were retrieved for further evaluation. Six 
articles were excluded on the basis of (i) duplicates of the same study (n=4); (ii) outcome not relevant (n=1) 
and (iii) review article (n=1). This left a total of 22 articles for inclusion in the review.(1, 3, 9, 22-40)   
 
Study characteristics and quality 
All 22 studies were based on observational cohort designs (21 retrospective cohorts and 1 prospective cohort), 
altogether comprising of 17,391 patients with COVID-19 (Table 1). Sixteen studies were based in China and 
six based in the United States. The average age at baseline ranged from 46 to 71 years, with a weighted mean 
(standard deviation, SD) of 60 (5) years. All studies enrolled both male and female patients. Hospital stay or 
follow-up duration ranged from 2 to 28 days with a weighted mean (SD) of 7.0 (4.0) days. The overall NOS 
methodological quality scores of studies ranged from 4 to 6.  
 
Prevalence of pre-existing renal conditions 
Across 20 studies providing relevant data, the prevalence of pre-existing CKD in COVID-19 patients ranged 
from 0.7% to 47.6%, with a pooled random effects prevalence (95% CI) of 5.2% (2.8-8.1; I2 =98%; 95% CI 
97, 98%; p for heterogeneity<0.01) (Figure 2). The 95% prediction interval for the summary prevalence was 
0.0 to 23.1%, suggesting that the true prevalence of pre-existing CKD for any single new study will usually 
fall within this range. The prevalence of pre-existing end-stage kidney disease based on pooled analysis of two 
studies was 2.3% (1.8-2.8) (Figure 2).  
 
Incidence of renal complications 
Over hospital stays ranging from 2 to 28 days following admission, the pooled incidence for AKI (n=22 
studies) was 11.0% (7.4-15.1; I2 =97%; 95% CI 97, 98%; p for heterogeneity<0.01) (Figure 3). For 14 studies 
reporting data on the definition of AKI, 12 defined AKI according to Kidney Disease Improving Global 




for RRT (n=3 studies) and acidosis (n=2 studies) were 12.5% (10.1-15.0), 6.8% (1.0-17.0) and 5.0 (3.2-7.2) 
respectively. (Figure 3). Based on the report by a single study, the incidence of alkalosis was 6.9 (4.5-10.6).  
Given AKI was the outcome commonly reported by studies (22 studies) and with the substantial 
heterogeneity between contributing studies, we explored for potential sources of heterogeneity using stratified 
analysis and random effects meta-regression. There was statistically significant evidence of effect 
modification on the incidence of AKI by location (p-value for meta-regression=0.03) and pre-existing CKD 
(p-value for meta-regression<0.001). There was no evidence of effect modification by age (Figure 4).  
 
Discussion 
In hospitalised patients with renal manifestations of COVID-19, the prevalence of pre-existing CKD was 
5.2% and that for end-stage kidney disease was 2.3%. Over hospital stays ranging from 2 to 28 days, AKI was 
the common outcome reported by studies; however electrolyte disturbance (hyperkalaemia) was the most 
frequent renal complication with an incidence of 12.5% followed by AKI and RRT at 11.0% and 6.8% 
respectively. Other reported complications included acidosis and alkalosis. Subgroup analyses suggested 
evidence of effect modification by location and pre-existing history of CKD on the incidence of AKI; 
incidence of AKI was higher in the US population (than the Chinese population) and among groups with 
higher prevalence of pre-existing CKD (than those with lower prevalence). However, AKI incidence was 
comparable in younger (<60 years) and older (≥60 years) individuals. 
Though COVID-19 predominantly affects the respiratory system, there is involvement of multiple 
organs, such as the gastrointestinal system, the cardiovascular system, the liver as well as the kidneys. These 
multiple organ disturbances may then interact with each other, which correlates with the severity of the 
disease. The virus SARS-CoV-2 is known to enter human lung cells by binding to angiotensin-converting 
enzyme 2 (ACE2).(42) The multiorgan involvement of SARS-CoV-2 has been linked to the wide distribution 
of ACE2 in the body; the highest expression of ACE2 is found in the ileum and kidneys.(43, 44)  In the 
kidney, ACE2 is expressed on several cells including mesangial cells, podocytes, parietal epithelium of the 
Bowman’s Capsule, and the collecting ducts.(45) Though the mechanisms for the renal manifestations of 
COVID-19 are still elusive, a complex multifactorial pathway has been proposed and it includes: (i) direct 




angiotensin-aldosterone system (RAAS) homeostasis;(44) (iii) lung protective fluid management strategy 
during treatment of ARDS(40) and (iv) as a result of a systemic inflammatory response “cytokine storm”.(44)  
COVID-19 represents a great medical challenge and appears to have multisystem effects which 
include renal manifestations. The current data based on up-to-date evidence suggests that AKI is commonly 
reported as a complication among patients with COVID-19. In addition to pre-existing CKD being associated 
with severe illness or death in COVID-19,(5)  it is also an independent risk factor for AKI.(47) Consistently, 
our study findings showed that groups with higher prevalence of pre-existing CKD might have higher 
incidence of AKI. Emerging evidence also suggests that renal manifestations of COVID-19 are also associated 
with increased risk of severe COVID-19 and fatal outcomes.(10, 30) Monitoring of markers of kidney 
function during hospitalization for COVID-19 could help in the identification of patients who at high risk for 
worse outcomes, to enable early and more aggressive intervention. The current evidence provides better 
insight on the extent of kidney damage by COVID-19. However, more work is needed to help us better 
understand the pathophysiology underlying renal manifestations of COVID-19, to help in the identification of 
effective management strategies. 
We have provided up-to-date data on the different renal manifestations of COVID-19 as well as their 
incidence rates. In addition, prevalence estimates of common renal comorbidities have also been presented. 
Other strengths of this study include ability to synthesise the data quantitatively as well as exploration for 
sources of heterogeneity. There were some limitations which were mostly inherent and included (i) inability to 
generalise the findings and the possibility of patient overlap, given that the majority of studies were based in 
China; (ii) the definition of CKD and classification into stages were not reported by included studies; (iii) a 
number of studies did not report on the definition for AKI; however, the majority defined AKI according to 
KDIGO criteria; (iv) studies reporting on the complications of acidosis and alkalosis did not distinguish 
whether these outcomes were of renal or lung origin; (v) one study reported an outcome of electrolyte 
disturbance, but did not provide a definition of this; (vi) the potential for differences in the timing during 









Aggregate up-to-date synthesis of the existing literature suggests that the most frequent renal complications 
among patients hospitalised with COVID-19 are electrolyte disturbance (particularly hyperkalaemia), AKI 
and the need for RRT. Aggressive monitoring and management of these renal complications may help in the 
prediction of more favourable outcomes.  
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Figure 1. Selection of studies included in the meta-analysis 
109 Potentially relevant citations identified
From MEDLINE, Embase and reference list 
of relevant studies
81 excluded on the basis of title 
and/ or abstract
6 Articles excluded due to:
4 Duplicates of same study
1 Outcome not relevant
1 Review article
22 Articles included in review




































Figure 2. Prevalence of pre-existing renal conditions in COVID-19 patients 
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Table 1. Characteristics of included studies 
Author, year of 
publication 
Source of data Country 







No. of patients AKI cases 
NOS 
score 
Aggarwal, 2020 UnityPoint Clinic USA March - April 2020 67.0 75 2.0 16 11 4 
Arentz, 2020 Evergreen Hospital in Kirkland, Washington USA Feb - March 2020 70.0 52 5.2 21 4 4 
Cao, 2020 Zhongnan Hospital of Wuhan University China Jan - Feb 2020 54.0 52 11.0 102 20 4 
Chen, 2020 Tongji Hospital in Wuhan China Jan - Feb 2020 62.0 62 13.0 274 29 4 
Cheng, 2020 Tertiary teaching hospital China  NR 63.0 52.4 10.0 701 36 6 
Guan, 2020 National Health Commission China Dec - Jan 2020 47.0 58.1 12.0 1099 6 4 
Guo, 2020 Seventh Hospital of Wuhan City China Jan - Feb 2020 58.5 48.7 16.3 187 18 5 
Huang, 2020 Jin Yintan Hospital, Wuhan China Dec - Jan 2020 49.0 73 7.0 41 3 4 
Liu, 2020 Shenzhen Third People’s hospital China Dec - Jan 2020  NR 66.7 8.6 12 2 4 
Phipps, 2020 New York-Presbyterian network USA March – April 2020 65.0 57.0 6.0 2,273 NR 6 
Price-Haywood, 2020 (W) Ochsner Health in Louisiana USA March – April 2020 55.5 45.7 7.0 1,030 34 6 
Price-Haywood, 2020 (B) Ochsner Health in Louisiana USA March – April 2020 53.6 37.7 6.0 2,451 163 6 
Richardson, 2020 12 Hospitals in New York-Northwell Health system USA March - April 2020 63.0 60.3 4.5 5700 523 4 
Ruan, 2020 Jin Yin-tan Hospital and Tongji Hospital China  NR 57.7 68 10.1 150 23 4 
Shi,2020 Renmin Hospital of Wuhan University China Jan - Feb 2020 64.0 49.3  NR 416 8 6 
Wang, 2020 Zhongnan Hospital of Wuhan University China Jan, 2020 56.0 54.3 7.0 138 5 4 
Wang, 2020b Renmin Hospital of Wuhan University China Jan - Feb 2020 71.0 49 28.0 339 27 4 
Wang, 2020c 
Zhongnan Hospital of Wuhan University and Xishui 
People’s Hospital China Up to Feb, 2020 51.0 53.3 11.0 107 14 5 
Yang, 2020 Wuhan Jin Yin-tan hospital China Dec - Jan 2020 59.7 67 10.0 52 15 4 
Zhao, 2020 Jingzhou Central Hospital China Jan - Feb 2020 46.0 53.8 NR 91 5 4 
Zhao, 2020b 
Shouyi and East districts of Renmin Hospital of Wuhan 
University China Jan – Feb 2020 61.0 46.6 7.0 1,000 29 4 
Zhou, 2020 Jinyintan Hospital & Wuhan Pulmonary Hospital China Dec - Jan 2020 56.0 62 11.0 191 28 5 









Appendix 1 PRISMA checklist 
Appendix 2 MOOSE checklist 
Appendix 3 MEDLINE literature search strategy 









No Checklist item 
Reported on page 
No 
Title 




2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, 
conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known Introduction 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, 
provide registration information including registration number 
Methods 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years 
considered, language, publication status) used as criteria for eligibility, giving rationale 
Methods 
Information sources 7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
Methods 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated 
Appendix 3 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators 
Methods 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
Methods 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis 
Methods 
Summary measures 13 State the principal summary measures (such as risk ratio, difference in means). Methods 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
Methods 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 
selective reporting within studies) 
Methods 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified 
Methods 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram 
Results, Figure 1 
Study 
characteristics 
18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up 
period) and provide the citations 
Results, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). Results  
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each 
intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency Results, Figures 2-4;  
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable 






24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
Discussion 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 
incomplete retrieval of identified research, reporting bias) 
Discussion 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and role 





Appendix 2. MOOSE checklist  
 
Renal complications in COVID-19: A systematic review and meta-analysis 
 
 
Criteria Brief description of how the criteria were handled in the review 
Reporting of background   
 Problem definition Renal manifestations of COVID-19 are not clearly defined. 
 Hypothesis statement (i) What are the renal complications associated with COVID-19? 
(ii) What is the incidence of these complications? 
(iii) Are patients with pre-existing renal morbidities more susceptible to these 
renal complications? 
 
 Description of study outcomes Renal complications 
 Type of exposure  Prevalence and incidence estimates 
 Type of study designs used Observational cohort designs and clinical studies 
 Study population Adult patients with COVID-19 
Reporting of search strategy should include  
 Qualifications of searchers Setor K. Kunutsor, PhD 
 Search strategy, including time period 
included in the synthesis and keywords 
Time period: from inception to 14 June 2020 
The detailed search strategy can be found in Appendix 3 
 Databases and registries searched MEDLINE, Embase and The Cochrane Library 
 Search software used, name and version, 
including special features 
OvidSP was used to search Embase and MEDLINE 
EndNote X9 used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  The 
citation list for excluded studies are available on request. 
 Method of addressing articles published 
in languages other than English 
Not applicable 
 Method of handling abstracts and 
unpublished studies 
Not applicable 
 Description of any contact with authors None 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled for 
assessing the hypothesis to be tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 
 Rationale for the selection and coding of 
data 
Data extracted from each of the studies were relevant to the population 
characteristics, study design, exposure, and outcome. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis of 
different adjustment levels and performed sub-group analyses to evaluate 
differences in the overall estimates according to levels of adjustment. 
 Assessment of study quality, including 
blinding of quality assessors; 
stratification or regression on possible 
predictors of study results 
Study quality was assessed based on the nine-star Newcastle–Ottawa Scale 
using pre-defined criteria namely: population representativeness, 
comparability (adjustment of confounders), ascertainment of outcome. 
Sensitivity analyses by several quality indicators such as study size, duration 
of follow-up, and adjustment factors. 
 Assessment of heterogeneity Results 
 Description of statistical methods in 
sufficient detail to be replicated 
Described in methods section 
 Provision of appropriate tables and 
graphics 
Table 1; Figures 1-4 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Figure 2-4 
 Table giving descriptive information for 
each study included 
Table 1 
 Results of sensitivity testing 
 
Not applicable  
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary estimates 
Reporting of discussion should include  






 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria in 
methods section. 
 Assessment of quality of included studies Brief discussion included in ‘Methods’ section 
Reporting of conclusions should include  
 Consideration of alternative explanations 
for observed results 
Discussion 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend large-scale studies when more data becomes available 






Appendix 3: MEDLINE literature search strategy 
 
1     exp Acute Kidney Injury/ (45784) 
2     exp Renal Insufficiency/ (171007) 
3     exp Proteinuria/ (38920) 
4     exp Hematuria/ (11861) 
5     exp Albuminuria/ (14899) 
6     kidney replacement.mp. (227) 
7     exp Kidney Transplantation/ (94773) 
8     electrolyte imbalance.mp. (6681) 
9     exp Acidosis/ (31908) 
10     exp Alkalosis/ (4723) 
11     exp Hyperkalemia/ (5857) 
12     COVID-19.mp. (5083) 
13     SARS-CoV-2.mp. (1378) 
14     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (331623) 
15     12 or 13 (5233) 
16     14 and 15 (18) 
17     limit 16 to (english language and humans and yr="2019 -Current") (11) 
Each part was specifically translated for searching alternative databases. 
 
Updated MEDLINE literature search strategy 
1     COVID-19.mp. (9980) 
2     SARS-CoV-2.mp. (3014) 
3     exp Kidney/ (348489) 
4     renal.mp. (674103) 
5     1 or 2 (10295) 
6     3 or 4 (846324) 
7     5 and 6 (111) 









Appendix 4: Definition of acute kidney injury by eligible studies 
 
Author, year of publication AKI definition 
  
Argenziano, 2020 Definition not specified 
Aggarwal, 2020 NR 
Arentz, 2020 Defined by criteria from KDIGO and the International Society of Nephrology 
Cao, 2020 NR 
Chen, 2020 
Identified on the basis of the highest serum creatinine level according to the 
KDIGO criteria 
Cheng, 2020 
Increase in serum creatinine by 0.3 mg/dl within 48 hours or a 50% increase 
in serum creatinine from baseline within 7 days according to the KDIGO 
criteria 
Guan, 2020 
Based on the highest serum creatinine level and urine output according to the 
KDIGO criteria 
Guo, 2020 NR 
Huang, 2020 
Identified on the basis of the highest serum creatinine level or urine output 
according to the KDIGO criteria 
Liu, 2020 NR 
Phipps, 2020 NR 
Price-Haywood, 2020 NR 
Richardson, 2020 
Increase in serum creatinine by 0.3 mg/Dl or more (≥26.5 μmol/L) within 48 
hours or an increase in serum creatinine to 1.5 times or more baseline within 
the 
prior 7 days compared with the preceding 1 year of data in acute care medical 
records according to KDIGO criteria 
Ruan, 2020 NR 
Shi,2020 Defined according to KDIGO criteria 
Wang, 2020 Defined according to KDIGO criteria 
Wang, 2020b Defined according to KDIGO criteria 
Wang, 2020c Defined according to KDIGO criteria 
Yang, 2020 Identified on the basis of serum creatinine according to KDIGO criteria 
Zhao, 2020 Identified according to elevated creatinine and uric acid levels 
Zhao, 2020b 
Highest serum creatinine level increased by more than 26.5 μmol/L (0.3 
mg/dL) within 48 hours; serum creatinine exceeded the baseline value by 1.5-
fold (confirmed or estimated to occur within 7 days); urine output <0.5 ml/kg 
* h), lasting more than 6 hours. 
Zhou, 2020 Defined according to KDIGO criteria 
 
AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcomes; NR, not reported 
 
